1. Introduction {#Section1}
===============

A small portion (5-10%) of bone fracture patients have impaired healing, eventually causing nonunion bone fractures and thus prolonging pain and disability [@B1]. Nonunion is routinely classified into two groups, namely, hypertrophic and atrophic, according to its radiological appearance [@B2], [@B3]. Hypertrophic nonunion has exuberant callus formation and results from inadequate immobilization of the fracture [@B2], [@B3]. Atrophic nonunion is absent of callus, bone ends and lacks vascularity, and it is caused by inadequate immobilization and blood supply [@B2], [@B3]. The most common treatment of nonunion is surgery, which is mainly devoted to stabilizing the nonunion area through inserting a bone graft to stimulate vasculogenesis and osteogenesis [@B4]. However, little is known regarding the molecular pathogenesis of nonunion [@B4]. Although only a small percentage of fractured patients eventually lead to nonunion, it imposes a heavy burden on families and society [@B1]-[@B4]. Thus, we are interested in studying the molecular mechanisms that cause nonunion.

The gene expression procedures that determine specific biological processes (e.g., cell differentiation and cell cycle progression) are controlled by numerous transcription factors (TFs) and their associated cofactors (e.g., corepressors and chromatin regulators) [@B5]-[@B8]. Importantly, dysregulation of these gene expression programs can cause a broad range of diseases, such as cancer and cardiovascular disease [@B5]-[@B8]. Mammals express numerous transcriptional corepressors to regulate gene expression in coordination with TFs [@B9]-[@B12]. The carboxyl-terminal binding proteins (CtBPs), a family of corepressors that have been well studied, form transcriptional complexes with histone acetyltransferases (e.g., p300, CBP and PCAF) [@B13]-[@B16], histone deacetylases (e.g., HDAC1, 2, 3 and 4) [@B13]-[@B16], and TFs (e.g., KLF3, KLF8, KLF12, FOXP2, NF-κB, TCF4 and ZNF750) [@B13]-[@B20]. Commonly, CtBPs interact with other proteins directly through a conserved PXDLS (X represents any residue) motif [@B21], [@B22], and the formed transcriptional complex binds to gene promoters and helps turn genes off [@B21], [@B22]. CtBPs are broadly expressed at high levels in many organs, including embryo, eyes, brain and heart, and therefore have multiple biological roles in these tissues [@B23]-[@B26]. In recent years, CtBPs, especially CtBP1, have been widely found to function as oncogenes in many cancer types [@B15], [@B27]-[@B30]. Overexpression of *CtBP1* in cancer cells disrupts gene expression networks and affects cell behavior, such as cell proliferation, invasion, migration and the epithelial-mesenchymal transition (EMT) [@B15], [@B27]-[@B30]. However, there are currently no reports showing that CtBPs are involved in the process of bone formation. Human CtBP1 and CtBP2 share amino acid sequence homology and crystal structure similarity with NADH-dependent dehydrogenases, and they can utilize NADH/NAD^+^ as a cofactor [@B15], [@B31]-[@B33]. Emerging evidence indicates that CtBPs form a homodimer or a heterodimer through a large predominately hydrophobic dimerization interface within the nucleotide-binding domain (NBD) under a high NADH level condition, which causes the dissociation of the CtBP-associated transcriptional complex [@B15], [@B16]. Thus, the NADH level determines the dimerization of CtBPs and the dissociation of the CtBP-TF complex, eventually contributing to the regulation of the expression of downstream targets [@B15], [@B16], [@B32], [@B34].

Runt-related transcription factor 2 (Runx2), a critical member of the Runx TF family, mainly functions to control osteoblast development and bone formation through regulating numerous genes, such as osteocalcin (*OSC*) [@B35], alkaline phosphatase (*ALPL*) [@B35], osteopontin (*SPP1*) [@B36], collagen 1a1 (*COL1A1*) [@B36], integrin binding sialoprotein (*IBSP*) [@B36], [@B37], and matrix metallopeptidases 9 and 13 (*MMP9* and *13*) [@B36]- [@B38]. Interestingly, Runx2 can also interact with HDAC3 and p300 to regulate the expression of genes involved in bone formation [@B39]. For example, Runx2 interacts with HDAC3 to repress *OSC* expression [@B39] while Runx2 interacts with p300 to activate *MMP13* expression [@B40]. Recently, Runx2 has been reported to function as a target of miR-628-3p and play roles in the pathogenesis of atrophic nonunion [@B41].

In the present study, by detecting CtBP levels in a large number of atrophic nonunion clinical samples, we found that *CtBP2*, but not *CtBP1*, was significantly overexpressed in nonunion samples compared to healthy controls. To investigate how CtBP2 is involved in nonunion pathogenesis, we performed microarray, LC-MS/MS mass spectrometry and chromatin immunoprecipitation (ChIP) experiments and found that CtBP2 can form a transcriptional complex with p300 and Runx2, which ultimately regulates the expression of many genes related to bone development and differentiation, such as *OSC*, *ALPL*, *SPP1*, *COL1A1*, *IBSP* and *MMP13*. In addition, we also detected the expression of the CtBP-p300-Runx2 complex and its downstream target genes in both high and low intracellular NADH conditions. Our results indicated that atrophic nonunion osteoblast cells had decreased NADH levels, which resulted in the dissociation of the CtBP2 homodimer and therefore enhanced its binding and inhibition of the p300-Runx2 complex, causing the downregulation of their targets and leading to the occurrence of atrophic nonunion.

2. Materials and methods {#Section2}
========================

2.1 Tissue samples {#Section2.1}
------------------

Patients who had fibular head fracture and underwent surgery and therapy from May 2012 to April 2015 at the Department of Orthopedics of Honghui Hospital were selected for this study. Twenty-four tissue samples were collected from the bony callus formed around the steel plates in normal healing patients, and the other 24 tissue samples were taken from the scar tissues of atrophic nonunion patients. The tissue samples were acquired with written informed consent from patients following protocols approved by the ethical board of Xi\'an Jiaotong University. The basic information of these patients is summarized in Supplementary Table [1](#SM0){ref-type="supplementary-material"}. All of the related experimental procedures were strictly performed following protocols approved by the ethical board of Xi\'an Jiaotong University.

2.2 Human primary osteoblast cell isolation, culture and transfection {#Section2.2}
---------------------------------------------------------------------

Primary osteoblasts from healthy controls and atrophic nonunion samples were isolated following a method previously described [@B42]. Briefly, samples were minced into 1 mm pieces and digested with 1.25 mg/mL collagenase (Thermo Fisher Scientific, USA, \#17100017) in Hank\'s Balanced Salt Solution (HBSS) (Thermo Fisher Scientific, \#14025126) with shaking at a speed of 20 rpm for 30 min. The released cells were discarded and then washed with Dulbecco\'s Modified Eagle Medium (DMEM) (Thermo Fisher Scientific, \#12491015) solution three times. Bone pieces were subsequently treated with 4 mM EGTA and 1.25 mg/mL collagenase for 20 min and 30 min, respectively. The released cells were collected with a 100-μm nylon cell strainer and subsequently cultured in DMEM medium at 37°C with 5% CO~2~ for 7 days to ensure that the outgrowing cells adhere to the dishes. The plasmid transfection was performed using HiPerFect Transfection Reagent (QIAGEN, USA, \#301705) following the manufacturer\'s instructions.

2.3 Immunoprecipitation (IP) and mass spectrometry analysis {#Section2.3}
-----------------------------------------------------------

The IP analysis was performed as previously described [@B43]. Briefly, the primary HOB cells expressing *pCDNA3-2xFlag-3xHA-CtBP2* or *pCDNA3-2xFlag-3xHA were* lysed with RIPA buffer (Sigma, USA, \#R0278) supplemented with complete protease inhibitor (Roche, USA, \#11697498001). Cell lysates were subjected to a two-step purification procedure. First, the centrifuged cell lysate was incubated with anti-Flag-agarose (Sigma, USA, \#A4596) at 4°C for 6 hours. Then, the protein-bound beads were washed with RIPA buffer five times, followed by elution with Flag peptide (Sigma, \#F3290) for four hours at room temperature. The resulting proteins were immunoprecipitated with anti-HA-agarose for at 4°C for 6 hours, and after washing five times with RIPA buffer, the HA-CtBP2 protein complex was loaded onto SDS-PAGE gels for electrophoresis, followed by staining with Coomassie Brilliant Blue R 250 (Thermo Fisher Scientific, \#20278). The stained proteins were cut into small pieces, followed by digestion with trypsin. The resulting proteins were analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS), and the obtained data were used to search the NCBI database using the MASCOT search engine (V.2.3).

2.4 Coimmunoprecipitation (Co-IP) and immunoblot analysis {#Section2.4}
---------------------------------------------------------

The primary HOB cells expressing pCDNA3-2xFlag-CtBP2+pCDNA3-6xMyc-p300, pCDNA3-2xFlag-CtBP2+pCDNA3-6xMyc, pCDNA3-2xFlag+pCDNA3-6xMyc-p300, pCDNA3-2xFlag-CtBP2+pCDNA3-6xMyc-Runx2, pCDNA3-2xFlag-CtBP2+pCDNA3-6xMyc, pCDNA3-2xFlag+pCDNA3-6xMyc-Runx2, pCDNA3-2xFlag-Runx2+pCDNA3-6xMyc-p300, pCDNA3-2xFlag-Runx2+pCDNA3-6xMyc, or pCDNA3-2xFlag+pCDNA3-6xMyc-p300 *were* lysed with RIPA buffer supplemented with complete protease inhibitor. Cell lysates were centrifuged at 13,000 rpm for 15 min at 4°C. The resulting supernatant was incubated with anti-Flag-agarose and anti-Myc-agarose (Sigma, \#A7470) at 4°C for four hours. After washing five times with RIPA buffer, the IP products were detected via immunoblot analysis. The blots were probed with primary anti-Flag (Sigma, USA), anti-Myc (Sigma, \#F1804), anti-CtBP2 (BD Biosciences, USA, \#612044), anti-p300 (Santa Cruz Biotechnology, USA, \#sc-585), anti-GAPDH (Santa Cruz Biotechnology, \#sc-365062), or anti-Runx2 (Santa Cruz Biotechnology, \#sc-101145) antibodies, and the chemiluminescence signals were detected by autoradiography.

2.5 RNA isolation and quantitative real-time PCR (qRT-PCR) {#Section2.5}
----------------------------------------------------------

The total RNA was extracted using TRIzol reagent (Thermo Fisher Scientific, \#15596026) following the manufacturer\'s instructions. For each sample, 0.5 μg of RNA was used for reverse transcription to synthesize cDNA with a ProtoScript First Strand cDNA Synthesis Kit (New England Biolabs, USA, E6300S). The obtained cDNA was diluted 100-fold and subjected to gene expression determination by qRT-PCR with a SYBR Green Master Mix Kit (Bio-Rad, USA, \#1725271) using the primers listed in Supplementary Table [2](#SM0){ref-type="supplementary-material"}. The PCR procedure conditions were 95°C for 2 min, followed by 55 cycles of 95°C for 15 s and 68°C for 30 s. The individual gene expression was normalized against β-actin (*ACTB*) according to the 2^-ΔCt^ method.

2.6 Microarray analysis {#Section2.6}
-----------------------

The microarray analysis was performed as previously described [@B44]. Briefly, the total RNA was extracted using TRIzol reagent following the manufacturer\'s instructions, and the RNA quality was measured using an Agilent Bioanalyzer (Agilent Technologies, USA, G2939BA). A total of 2 μg of RNA of each sample was labeled with biotin and then synthesized into cRNA using a GeneChip 3\' IVT Express Kit (Thermo Fisher Scientific, \#902416), followed by fragmentation and incubation with the array chip (GeneChip Human Genome U133 Plus 2.0, Thermo Fisher Scientific, \#900466) for 12 hours at 45°C. After staining with streptavidin-phycoerythrin (SAPE) for 300 seconds at 35°C, arrays were scanned using a GeneArray^TM^ Scanner. Data were obtained and analyzed using GeneSpring GX (Agilent Technologies Inc., USA).

2.7 Chromatin immunoprecipitation (ChIP) assay {#Section2.7}
----------------------------------------------

The ChIP assay was performed as previously described [@B45]. Briefly, cells were washed once with 1x PBS at room temperature and then crosslinked with 1x PBS containing 1% formaldehyde for 30 minutes. The fixed cells were sonicated to an average size of 300-500 bp, and cell lysates were subjected to chromatin precipitation with a Millipore ChIP Assay Kit (Millipore, USA, \#17295) following the manufacturer\'s protocol. Chromatin fragments were immunoprecipitated with the following antibodies: anti-CtBP1 (\#612042) and anti-CtBP2 (\#612044) from BD Biosciences, mouse IgG (\#sc-2025), anti-Pol II (\#sc-47701), anti-HDAC1 (\#sc-8410), anti-acetyl-histone H3 (\#sc-8655), anti-p300 (\#sc-585) and anti-Runx2 (\#sc-101145) from Santa Cruz Biotechnology. The immunoprecipitated DNA was analyzed by qRT-PCR using the primers listed in Supplementary Table [3](#SM0){ref-type="supplementary-material"}.

2.8 Statistical analysis {#Section2.8}
------------------------

All experiments in the current study were independently repeated at least three times. Statistical analyses were performed using SPSS version 22 software. Statistical significance was set at a *P*-value less than 0.05.

Results
=======

3.1 *CtBP2* is significantly overexpressed in atrophic nonunion tissues {#Section3.1}
-----------------------------------------------------------------------

The aberrant expression of *CtBPs* is closely associated with the occurrence of numerous diseases [@B27]-[@B30], and thus, we sought to detect whether they also play a role in the pathogenesis of atrophic nonunion. Accordingly, we collected 48 samples, including 24 tissues from patients with normal fracture healing and 24 tissues from patients with atrophic nonunion, and then examined the mRNA and protein levels of CtBPs in these tissues. Primarily, we performed qRT-PCR assays to detect *CtBP* mRNA levels, and our results indicated that the *CtBP1* mRNA level was slightly increased (∼1.4- to 1.8-fold) in nearly 80% (19/24) of the atrophic nonunion tissues compared to normal fracture healing tissues (Figures [1](#F1){ref-type="fig"}A and [1](#F1){ref-type="fig"}B). However, the *CtBP2* mRNA level was significantly increased (∼3- to 9-fold) in over 90% (22/24) of the atrophic nonunion tissues compared to the normal tissues (Figures [1](#F1){ref-type="fig"}C and [1](#F1){ref-type="fig"}D). Then, we detected both the CtBP1 and CtBP2 protein levels in four atrophic nonunion tissues and four normal tissues. Similar to their mRNA levels, we only observed a slight increase of the CtBP1 protein level (∼1.2- to 1.4-fold) (Figures [1](#F1){ref-type="fig"}E and [1](#F1){ref-type="fig"}F) but a significant increase of the CtBP2 level (∼3- to 5-fold) (Figures [1](#F1){ref-type="fig"}E and [1](#F1){ref-type="fig"}G) in four atrophic nonunion tissues. Osteoblast cells are useful tools in studying bone formation and development as well as the formation of atrophic nonunion. However, there were no commercial osteoblast cell lines from atrophic nonunion. Thus, we isolated the primary osteoblast cells from four normal fracture healing tissues (namely, HOB-1, HOB-2, HOB-3 and HOB-4) and four atrophic nonunion tissues (namely, AOB-1, AOB-2, AOB-3 and AOB-4) and measured the *CtBP* mRNA and protein levels in these osteoblast cells. Similarly, we also found that *CtBP1* mRNA and protein levels were only slightly increased, whereas the *CtBP2* mRNA and protein levels were significantly upregulated in AOB cells compared to HOB cells (Supplementary Figure [1](#SM0){ref-type="supplementary-material"}). Collectively, our data demonstrated that the overexpression of *CtBPs*, especially *CtBP2*, in atrophic nonunion tissues is a common phenomenon, which implies that *CtBP2* may play an important role in the pathogenesis of nonunion. Based on the results that *CtBP2* is more significantly induced than *CtBP1*, our following investigation will only focus on exploring how*CtBP2* overexpression leads to the occurrence of nonunion.

3.2 *Runx2* is dramatically downregulated in atrophic nonunion tissues {#Section3.2}
----------------------------------------------------------------------

Given that CtBP2 functions as a corepressor that associates or directly interacts with TFs to regulate gene expression [@B15], [@B27]-[@B30], we next sought to identify the TFs associated with CtBP2 in the pathogenesis of atrophic nonunion. For this purpose, we isolated mRNAs from three normal fracture healing tissues (HC-1, HC-2 and HC-3) and three atrophic nonunion tissues (AN-1, AN-2 and AN-3), followed by subjecting them to microarray analysis. Overall, a total of 262 genes were identified as having aberrant levels in atrophic nonunion tissues compared to healthy controls (Supplementary Table [4](#SM0){ref-type="supplementary-material"}). Among them, 127 genes were upregulated, and the other 135 genes were downregulated (Supplementary Table [4](#SM0){ref-type="supplementary-material"}). In Figure [2](#F2){ref-type="fig"}A, we showed the top 30 upregulated and 30 downregulated genes with the most significant changes. Interestingly, we found *CtBP2* in these upregulated genes. Among the downregulated genes, we found *p300*, *Runx2*, and a series of Runx2 target genes, such as *COL1A1*, *SPP1*, *OSC*, *ALPL*, *IBSP* and *MMP13* (Figure [2](#F2){ref-type="fig"}A, Supplementary Table [4](#SM0){ref-type="supplementary-material"}). To verify the reliability of the microarray results, we randomly chose three upregulated genes (*SPHK1*, *DKK1* and *CDH2*) and three downregulated genes (*p300*, *Runx2* and *BMP2*) for qRT-PCR verification in all clinical samples. Consistent with the microarray results, the qRT-PCR results indicated that the expression levels of *SPHK1*, *DKK1* and *CDH2* were significantly upregulated while the expression levels of *p300*, *Runx2* and *BMP2* were dramatically downregulated in all atrophic nonunion tissues compared to the healthy controls (Figures [2](#F2){ref-type="fig"}B-[2](#F2){ref-type="fig"}G). These results, together with previous reports that CtBPs directly interact with p300 through the PXDLS motif and that p300 forms a complex with Runx2 to initiate transcription [@B21], [@B22], [@B39], [@B40], imply that there is a high possibility that CtBP2 forms a transcriptional complex with p300 and Runx2.

3.3 CtBP2 forms a transcriptional complex with p300 and Runx2 {#Section3.3}
-------------------------------------------------------------

To verify whether CtBP2 can form a complex with p300 and Runx2 *in vivo* and identify other members of this complex, we primarily constructed a two-epitope-tagged vector *pCDNA3-2xFlag-3xHA-CtBP2* and transfected it into HOB-1 primary osteoblast cells. After a two-step purification method with anti-Flag-agarose and anti-HA-agarose to remove unspecific binding proteins, the CtBP2-associated proteins were enriched (Figure [3](#F3){ref-type="fig"}A) and subjected to LC-MS/MS analysis. By applying the obtained peptides for comparison in the NCBI database, we identified a total of 145 proteins that were associated with CtBP2 (Supplementary Table [5](#SM0){ref-type="supplementary-material"}). As expected, we identified p300, Runx2 and HDAC1 in these 145 CtBP2 associated proteins (Supplementary Table [5](#SM0){ref-type="supplementary-material"}). Next, we verified the association of CtBP2 with p300, Runx2 and HDAC1 in materials used for LC-MS/MS analysis. As shown in Figure [3](#F3){ref-type="fig"}B, HA-CtBP2 can pull down p300, Runx2 and HDAC1, but not the negative control that was immunoprecipitated from cells expressing a *pCDNA3-2xFlag-3xHA* empty vector. In addition, we also detected if CtBP2 can directly interact with p300 and Runx2. Accordingly, we transfected HOB-1 cells with the following combinations of plasmids: *pCDNA3-2xFlag-CtBP2* + *pCDNA3-6xMyc-p300*, *pCDNA3-2xFlag-CtBP2* + *pCDNA3-6xMyc*, *pCDNA3-2xFlag* + *pCDNA3-6xMyc-p300*, *pCDNA3-2xFlag-CtBP2* + *pCDNA3-6xMyc-Runx2*, and *pCDNA3-2xFlag* + *pCDNA3-6xMyc-Runx2*. After Co-IP with either anti-Flag-agarose or anti-Myc-agarose to obtain Flag-CtBP2, Myc-p300 and Myc-Runx2 proteins, we subjected them to immunoblots to determine the direct interactions between CtBP2 and p300 as well as CtBP2 and Runx2. As shown in Figures [3](#F3){ref-type="fig"}C and [3](#F3){ref-type="fig"}D, Flag-CtBP2 and Myc-p300 were able to pull each other down, suggesting direct interactions between them. However, we did not find direct interactions between Flag-CtBP2 and Myc-Runx2 (Figures [3](#F3){ref-type="fig"}E and [3](#F3){ref-type="fig"}F).

Given that previous publications have reported the direct interaction between p300 and Runx2 [@B40], we next sought to verify this interaction in the primary HOB-1 cells. For this purpose, we transfected HOB-1 cells with the following combinations of plasmids: *pCDNA3-2xFlag-Runx2* + *pCDNA3-6xMyc-p300*, *pCDNA3-2xFlag-Runx2* + *pCDNA3-6xMyc*, and *pCDNA3-2xFlag* + *pCDNA3-6xMyc-p300*. After Co-IP with either anti-Flag-agarose or anti-Myc-agarose, the purified Flag-Runx2 and Myc-p300 proteins were subjected to immunoblots to determine the direct interactions between p300 and Runx2. Our results indicated that both Flag-Runx2 and Myc-p300 were able to pull each other down (Supplementary Figures [2](#SM0){ref-type="supplementary-material"}A and 2B), suggesting direct interactions between them. These results clearly indicated that CtBP2 formed a complex with p300 and Runx2 through the direct interactions between CtBP2-p300 and p300-Runx2.

In Supplementary Figure [1](#SM0){ref-type="supplementary-material"}, we showed that *CtBP2* mRNA and protein levels were significantly upregulated in AOB cells compared to HOB cells. We next sought to examine the *p300* and *Runx2* levels in AOB primary osteoblast cells. By subjecting cell lysates to immunoblot analyses, interestingly, we found that the protein levels of p300 and Runx2 were significantly reduced in AOB cells, which was opposite to the CtBP2 level (Supplementary Figure [2](#SM0){ref-type="supplementary-material"}C). To further confirm this observation, we transfected *CtBP2*-specific siRNA into two HOB cell lines (HOB-1 and HOB-2) and in two AOB cell lines (AOB-1 and AOB-2) to knockdown the *CtBP2* level. As shown in Supplementary Figure [2](#SM0){ref-type="supplementary-material"}D, p300 and Runx2 protein levels were significantly increased with the downregulation of *CtBP2*. These results implied that CtBP2 plays an inhibitory role in regulating p300-Runx2 complex formation.

3.4 The CtBP2-p300-Runx2 transcriptional complex inhibits the expression of genes involved in bone formation and differentiation {#Section3.4}
--------------------------------------------------------------------------------------------------------------------------------

As mentioned earlier, *Runx2* can regulate the expression of a number of critical members (e.g., *OSC*, *ALPL*, *SPP1*, *COL1A1*, *IBSP* and *MMP13*) involved in osteoblast development and bone formation [@B35]-[@B40], and we also identified that these genes were significantly downregulated in AOB cells in microarray assays (Supplementary Table [4](#SM0){ref-type="supplementary-material"}). To verify this observation, we measured the mRNA levels of these genes in AOB primary osteoblast cells using *CUL4A* as a control, which was upregulated in atrophic nonunion tissues (Figure [2](#F2){ref-type="fig"}A). The qRT-PCR results indicated that the expressions of *OSC*, *ALPL*, *SPP1*, *COL1A1*, *IBSP* and *MMP13* were downregulated in AOB cells compared to HOB cells, with the most obvious decrease in AOB-3 cells (∼2.5-fold) (Figure [4](#F4){ref-type="fig"}A), which was contrary to the expression of *CtBP2*. To further determine if the expressions of these genes were correlated with the *CtBP2* level, we knocked down *CtBP2* with its specific siRNA in AOB and HOB cells and then examined these *Runx2* target gene levels. As shown in Figure [4](#F4){ref-type="fig"}B, the expression of *OSC*, *ALPL*, *SPP1*, *COL1A1*, *IBSP* and *MMP13* but not *CUL4A* was significantly upregulated with the downregulation of *CtBP2*. Moreover, we also examined the protein levels of OSC, COL1A1, SPP1, MMP13 and CUL4A, and found they showed similar patterns as their corresponding mRNA levels (Supplementary Figure [3](#SM0){ref-type="supplementary-material"}). These results demonstrated that *CtBP2* repressed the expression of *Runx2* downstream targets.

The transcriptional complex normally binds directly to promoter regions and initiates transcription [@B5]-[@B8]. To verify if the CtBP2-p300-Runx2 complex could bind to the promoters of these Runx2 target genes, we performed anti-CtBP2, anti-p300 and anti-Runx2 ChIP-coupled qRT-PCR assays in AOB and HOB cells using anti-CtBP1 and anti-IgG as controls. Our results revealed that CtBP2 occupancy on the promoters of these *Runx2* target genes was significantly increased in AOB cells compared to HOB cells (Figure [5](#F5){ref-type="fig"}A). However, CtBP1 cannot directly bind to the promoters of these genes because it had a similar occupancy to that of anti-IgG, which was significantly lower than CtBP2 occupancy (Figure [5](#F5){ref-type="fig"}A). As expected, the occupancies of p300 and Runx2 were dramatically decreased in AOB cells compared to HOB cells (Figure [5](#F5){ref-type="fig"}B). Given that TFs normally couple with RNA polymerase II (Pol II) and bind to gene promoters to begin transcription [@B46], [@B47], we further performed an anti-Pol II ChIP assay to compare Pol II occupancy on the promoters of *Runx2* target genes in AOB and HOB cells with and without *CtBP2* knockdown. The occupancy of Pol II was dramatically decreased in AOB cells compared to HOB cells (Figure [5](#F5){ref-type="fig"}C). Interestingly, all *Runx2* target genes displayed significantly increased Pol II binding to their promoters with *CtBP2* knockdown, ranging from 4- to 9-fold compared to the scrambled siRNA-treated cells (Figure [5](#F5){ref-type="fig"}C). In addition, we also performed anti-p300 and anti-Runx2 ChIP assays in AOB and HOB cells with and without *CtBP2* knockdown. The qRT-PCR results indicated that all *Runx2* target genes displayed significantly increased p300 or Runx2 binding to their promoters with *CtBP2* knockdown (Supplementary Figure [4](#SM0){ref-type="supplementary-material"}). These results suggested that CtBP2 acted as a repressor to inhibit the p300-Runx2 transcriptional complex and thereby limited Pol II binding as well as repressed the expression of *Runx2* target genes.

3.5 An elevated NADH level upregulates *Runx2* target gene levels in AOB cells {#Section3.5}
------------------------------------------------------------------------------

Numerous publications have reported that intracellular NADH level determines the formation of CtBP dimers and their associated binding partners [@B26]-[@B34]. Our above results indicated significant differences between CtBP2 and its transcriptional complex partners p300 and Runx2 in AOB and HOB cells. Thus, we speculated that the NADH levels in these two types of cells are also different. To test this hypothesis, we first determined the NAD^+^/NADH levels in AOB and HOB cells. As expected, our results showed that NAD^+^/NADH levels in AOB cells were significantly increased compared to HOB cells (Figure [6](#F6){ref-type="fig"}A), indicating that NADH levels in AOB cells were decreased. According to previous reports, the decreased NADH levels inhibited the formation of CtBP dimers [@B16], [@B34], which facilitates the tight binding of the CtBP monomer to p300 and inhibits downstream transcription [@B16], [@B26]-[@B34]. Based on this notion, we treated HOB and AOB cells with or without 200 μM cobalt chloride (CoCl~2~) and the combination of CoCl~2~ and 2-n-heptyl-4-hydroxyquinoline N-oxide (HQNO) to change intracellular NADH levels. The chemical CoCl~2~ can increase the NADH level [@B16], and HQNO is a high affinity inhibitor of NADH [@B48], [@B49]. As shown in Figure [6](#F6){ref-type="fig"}B, the CoCl~2~ treatment significantly increased the NADH levels in both HOB and AOB cells while the addition of HQNO reduced the NADH levels. Then, we measured the *CtBP2* mRNA levels in these treated cells. Interestingly, we did not observe an obvious change in the *CtBP2* mRNA level with either CoCl~2~ treatment alone or the combination of CoCl~2~ and HQNO (Figure [6](#F6){ref-type="fig"}C). In addition, we also examined the protein levels of CtBP2, p300, Runx2 and acetylated Runx2. As shown in Figure [6](#F6){ref-type="fig"}D, the CoCl~2~ treatment alone and combined treatment with CoCl~2~ and HQNO could not change the protein levels of CtBP2, p300 or Runx2. However, we found that the acetylated Runx2 was significantly upregulated with CoCl~2~ treatment but dramatically decreased with the addition of HQNO (Figure [6](#F6){ref-type="fig"}D). One possible explanation is that CtBP2 forms dimers with the increase of the NADH level, which reduces its inhibitory effect on p300 and enhances p300 activity, thereby facilitating the acetylation of Runx2.

Despite the fact that intracellular NADH level changes did not affect the mRNA and protein levels of CtBP2, p300 and Runx2, we speculated that the alterations of acetylated Runx2 with NADH level changes should affect its downstream targets. To verify this hypothesis, we examined the expression of Runx2 target genes in cells treated with CoCl~2~ and CoCl~2~+HQNO. Consistent with our expectation, CoCl~2~ treatment significantly increased the expression of Runx2 target genes in both AOB and HOB cells (Figure [6](#F6){ref-type="fig"}E), whereas the addition of HQNO markedly attenuated the expression of these genes (Figure [6](#F6){ref-type="fig"}E). In contrast, we did not find any change regarding *CUL4A* in these cells under different treatments (Figure [6](#F6){ref-type="fig"}E). In addition, we also performed ChIP-coupled qRT-PCR assays in HOB cells treated with CoCl~2~ and CoCl~2~+HQNO using anti-acetyl-Runx2. Our results revealed that the acetylated Runx2 occupancy on the promoters of *Runx2* target genes was significantly increased in HOB cells treated with CoCl~2~ compared to no treatment or CoCl~2~+HQNO treated cells (Supplementary Figure [5](#SM0){ref-type="supplementary-material"}). These results demonstrated that the elevated NADH level upregulated *Runx2* target gene levels through the increased occupancy of acetylated Runx2.

To verify that CtBP2 dimerization is a critical step for the regulation of *Runx2* target genes, we then performed a Co-IP assay to detect the interactions between p300 and wild-type CtBP2 or the nondimerizing mutant CtBP2-G189A in the low and high NADH conditions. Our results indicated that p300 was most abundant in HOB cells treated with CoCl~2~ (high NADH), which decreased dramatically in the conditions of no treatment and CoCl~2~+HQNO treatment (low NADH) (Figure [7](#F7){ref-type="fig"}A). Interestingly, the protein level of p300 in cells expressing *pCDNA3-2xFlag-CtBP2-G189A* mutant was much lower than cells expressing *pCDNA3-2xFlag-CtBP2* in different treatments (Figure [7](#F7){ref-type="fig"}A)*.* And more importantly, the changes in the NADH levels did not affect p300 level in cells harboring *CtBP2-G189A* mutant (Figure [7](#F7){ref-type="fig"}A). These results indicated that CtBP2 dimerization determined p300 level because the undimerized CtBP2 in low NADH condition preferred to bind to p300. Meanwhile, we also examined the expression of *Runx2* target genes in these conditions. Our results showed that the expression of *OSC*, *ALPL*, *SPP1*, *COL1A1*, *IBSP* and *MMP13* was significantly increased with the CoCl~2~ treatment compared to no treatment or CoCl~2~+HQNO treatment (Figure [7](#F7){ref-type="fig"}B) while their expressions were not changed in CtBP2-G189A-containing cells under different treatments (Figure [7](#F7){ref-type="fig"}B). These results suggested that CtBP2 dimerization might determine the expression of *Runx2* target genes.

3.6 HDACs are not required for the transcription of *Runx2* target genes {#Section3.6}
------------------------------------------------------------------------

Normally, CtBPs regulate gene transcription in two different manners: one is through interactions with acetyltransferases (e.g., p300, CBP and PCAF), and the other is through interactions with histone deacetylases (e.g., HDAC1 and 2) [@B16]. In our LC-MS/MS results, we also found that CtBP2 could immunoprecipitate with HDAC1 and 2. To investigate if HDAC1 and 2 are also involved in the pathogenesis of nonunion, we primarily detected HDAC1 and 2 mRNA and protein levels in HOB and AOB cells. The results showed that both the mRNA and protein levels of HDAC1 and 2 were not obviously changed in these two different cell sources (Supplementary Figures [6](#SM0){ref-type="supplementary-material"}A and 6B). In addition, we also knocked down *HDAC1* and *2* with their specific siRNAs in both HOB and AOB cells, followed by the detection of *Runx2* target gene expression. Our results indicated that the expressions of *OSC*, *ALPL*, *SPP1*, *COL1A1*, *IBSP* and *MMP13* were not changed with the knockdown of *HDAC1* and *2* (Supplementary Figure [6](#SM0){ref-type="supplementary-material"}C). These results suggested that *HDAC1* and *2* are not required for the transcriptional regulation of *Runx2* target genes in HOB and AOB cells. To further confirm this conclusion, we also performed ChIP-coupled qRT-PCR assays in AOB and HOB cells to evaluate the occupancies of HDAC1 and 2 on the promoters of *Runx2* target genes. Our results indicated that the occupancies of HDAC1, HDAC2 and the negative control IgG were not significantly different, suggesting that HDAC1 and 2 cannot bind to the promoters of these *Runx2* target genes (Supplementary Figure [6](#SM0){ref-type="supplementary-material"}D). These results suggested that HDAC1 was not required for the Runx2-mediated transcription in AOB and HOB cells.

4. Discussion {#Section4}
=============

CtBPs play important roles in the pathogenesis of many diseases including cancer and inflammation [@B16], [@B27]-[@B30]. However, their roles in bone formation and differentiation have not been reported. In this study, we found that *CtBP2*, but not *CtBP1*, is significantly overexpressed in atrophic nonunion tissues with a mechanism involved in the regulation of the p300-Runx2 transcriptional complex and its downstream targets. Our results clearly demonstrate that CtBP2 forms a dimer, thus relieving its inhibition of the p300-Runx2 transcriptional complex in normal cells (Figure [8](#F8){ref-type="fig"}A). However, in AOB cells, the dissociation of CtBP2 dimers mediated by a low NADH level represses the activity of p300, thus significantly inhibiting the expression of numerous *Runx2* target genes (Figure [8](#F8){ref-type="fig"}B), which ultimately leads to nonunion.

CtBP1 and CtBP2 share over 80% identical amino acid sequences, and they exhibit partially functional redundancy in previous studies [@B15]. In the present study, we found that *CtBP1* is only slightly upregulated (1.5- to 1.8-fold) in AOB cells compared to HOB cells while the *CtBP2* overexpression is more than 3-fold and even up to 9-fold in some samples. Although we only focused our studies on revealing *CtBP2* function, we cannot exclude the possibility that *CtBP1* is also involved in the occurrence of nonunion. In addition, we also did not clarify the mechanism regarding *CtBP2* overexpression in the current study, but in fact, we have started to investigate the underlying mechanisms using RNA sequencing (RNA-Seq). Our preliminary results show that several microRNAs are involved in the overexpression of *CtBP2*. By increasing or inhibiting the expression of these microRNAs, we found that the expression of *CtBP2* also changed (data not shown).

In the LC-MS/MS results, we found that CtBP2 could immunoprecipitate p300 as well as HDAC1 and 2, which have been previously reported to function as transcriptional coactivators and repressors in the regulation of gene expression by acetylating and deacetylating histones in the promoters of their targeted genes, respectively [@B15], [@B16], [@B34]. CtBPs have been previously shown to interact with p300 as well as HDAC1 and 2 through the PXDLS motif [@B15], [@B16], [@B34]. Compared to the dramatic decrease of p300, we did not find changes in the HDAC1 and 2 levels in AOB cells, suggesting that HDAC1 and 2 are not required, or at least do not play a major role, in the pathogenesis of nonunion. Previous studies have shown that NADH levels determine the manner in which CtBPs regulate gene expression [@B15], [@B16], [@B34]. We found that AOB cells have lower NADH levels than HOB cells, which contributes to the dissociation of the CtBP2 dimer. However, we do not know the exact reason for the reduction of NADH in AOB cells. By increasing or decreasing intracellular NADH levels as well as using the CtBP2-G189A mutant, we demonstrate that CtBP2 can alternatively associate with Runx2 and regulate its acetylation by a mechanism dependent on the transition between the dimer and monomer forms of CtBP2. These results are consistent with previous publications that found that CtBP1 represses p300 activity dependent on NADH while the CtBP1-G189A mutant suppresses p300 independent of NADH [@B15], [@B16], [@B34]. The high sensitivity of CtBP in responding to the NADH level changes implies that increasing NADH levels in the diet of nonunion patients may improve the formation of nonunion.

In conclusion, our findings demonstrate that intracellular NADH levels regulate *Runx2* target gene expression through a mechanism involving CtBP2 dimerization. Conditions that increase NADH levels facilitate CtBP2 dimerization and enhance p300 activity, whereas reduced NADH levels contribute to the formation of CtBP2 monomers and suppress p300-Runx2-mediated transcription.
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![**CtBP2 is overexpressed in atrophic nonunion tissues. (A** and **B)** The relative mRNA levels of CtBP1 in normal fracture healing tissues (HC, n=24) and atrophic nonunion tissues (AN, n=24) determined by qRT-PCR. \**P*\<0.05.**(C** and **D)** The relative mRNA levels of CtBP2 in the same tissues as (A) examined by qRT-PCR. \*\**P*\<0.001.**(E)** The protein levels of CtBP1 and 2 in HC (n=4) and AN (n=4) tissues. GAPDH was used as a control. **(F** and**G)** Statistical analysis of the relative protein levels of CtBP1 and 2 in (E). \**P*\<0.05. \*\**P*\<0.001.](ijbsv14p2023g001){#F1}

![**The aberrant gene expression profile in atrophic nonunion tissues. (A)** The heat maps of the top 30 downregulated and upregulated genes with the most significant changes in three atrophic nonunion tissues. The mRNAs from three normal fracture healing tissues (HC-1, HC-2 and HC-3) and three atrophic nonunion tissues (AN-1, AN-2 and AN-3) were subjected to microarray analysis. The red or green colors indicated differentially up- or downregulated genes, respectively. The red arrows indicated genes that were interesting. **(B-G)** Verification of gene levels identified in microarray analysis in 24 healthy tissues and 24 atrophic nonunion tissues. The qRT-PCR was performed to verify the expressions of three upregulated genes, including *SPHK1* **(B)**, *DKK1* **(C)**, and *CDH2* **(D)**, and three downregulated genes, including *p300* **(E)**, *Runx2* **(F)**, and *BMP2* **(G)**. \*\**P* \< 0.001.](ijbsv14p2023g002){#F2}

![**CtBP2 forms a complex with p300 and Runx2 *in vivo*. (A)***In vivo* pull-down of the Flag-HA-CtBP2-associated complexes. The HOB-1 cells were transfected with *pCDNA3-2xFlag-3xHA-CtBP2* or *pCDNA3-2xFlag-3xHA*. After 48 hours, the cells were lysed and subjected to IP analysis. The resulting protein complexes were loaded onto SDS-PAGE gel for separation and then stained with Coomassie Brilliant Blue R 250. The IgG and CtBP2 bands were indicated. **(B)** Verification of CtBP2-associated proteins identified in LC-MS/MS analysis. The protein samples used in (A) were used to verify the association of CtBP2, p300 and Runx2. **(C** and **D)** CtBP2 directly interacted with p300 in HOB-1 cells. The HOB-1 cells were cotransfected with *pCDNA3-2xFlag-CtBP2* + *pCDNA3-6xMyc-p300*, *pCDNA3-2xFlag-CtBP2* + *pCDNA3-6xMyc*, or *pCDNA3-2xFlag* + *pCDNA3-6xMyc-p300*. After 48 hours, the cells were lysed and subjected to IP analysis with either anti-Flag-agarose **(C)** or anti-Myc-agarose **(D)**. The pull-down products were then subjected to western blot with the antibodies indicated in the figures. **(E** and **F)** CtBP2 cannot directly interact with Runx2 in HOB-1 cells. The HOB-1 cells were cotransfected with *pCDNA3-2xFlag-CtBP2* + *pCDNA3-6xMyc-Runx2*, *pCDNA3-2xFlag* + *pCDNA3-6xMyc-Runx2*, or *pCDNA3-2xFlag-CtBP2* + *pCDNA3-6xMyc*. After 48 hours, the cells were lysed and subjected to IP analysis with either anti-Flag-agarose **(E)** or anti-Myc-agarose **(F)**. The pull-down products were then subjected to western blot with the antibodies indicated in the figures.](ijbsv14p2023g003){#F3}

![**Runx2 target genes are downregulated in AOB cells. (A)** Runx2 target genes are downregulated in AOB cells. The relative mRNA levels of *Runx2* target genes, including *OSC*, *ALPL*, *SPP1*, *COL1A1*, *IBSP* and *MMP13*, in HOB and AOB cells were determined by qRT-PCR. *CUL4A* was used as a control. \**P*\<0.05. **(B)** The expression of *Runx2* target genes was dependent on the *CtBP2* level. The HOB-1, HOB-2, AOB-1 and AOB-2 cells were transfected with control-siRNA or *CtBP2-siRNA*, respectively. After 48 hours, the cells were subjected to RNA isolation, followed by measuring the expression of Runx2 target genes by qRT-PCR. *CUL4A* was used as a control. \*\**P*\<0.001.](ijbsv14p2023g004){#F4}

![**The CtBP2-p300-Runx2 transcriptional complex specifically binds to the Runx2 target gene promoters. (A)** The CtBP2 was significantly enriched on the promoters of *Runx2* target genes in AOB cells. The HOB-1 and AOB-3 cells were subjected to ChIP assays with CtBP1, CtBP2 and IgG antibodies, followed by analysis with qRT-PCR to evaluate their binding to the promoters of *Runx2* target genes. *CUL4A* and *FOXM1* were used as controls. \*\**P*\<0.001. **(B)** The binding of p300 and Runx2 on the promoters of *Runx2* target genes was dramatically decreased in AOB cells. The HOB-1 and AOB-3 cells were subjected to ChIP assays with p300, Runx2 and IgG antibodies, followed by analysis with qRT-PCR to evaluate their binding to the promoters of Runx2 target genes. *CUL4A* and *FOXM1* were used as controls. \*\**P*\<0.001. **(C)** The binding of Pol II on the promoters of Runx2 target genes was dramatically decreased in AOB cells. The HOB-1 and AOB-3 cells were transfected with control siRNA and *CtBP2-siRNA* and subjected to ChIP assays with Pol II and IgG antibodies, followed by analysis with qRT-PCR to evaluate their binding to the promoters of Runx2 target genes. *CUL4A* and *FOXM1* were used as controls. \*\**P*\<0.001.](ijbsv14p2023g005){#F5}

![**NADH levels determine Runx2 target gene expression. (A)** The NAD^+^/NADH levels in AOB cells were significantly increased. Four HOB cell samples (1-4) and four AOB cell samples (1-4) were subjected to measure the NAD^+^/NADH levels. \*\**P*\<0.001. **(B)** The CoCl~2~ treatment dramatically decreased the NAD^+^/NADH levels. The HOB1 and AOB cells were treated with CoCl~2~ or CoCl~2~+HQNO, and then, the NAD^+^/NADH levels were measured. \*\**P*\<0.001. **(C)** Treatments with CoCl~2~ or CoCl~2~+HQNO cannot affect the CtBP2 mRNA level. The mRNAs from cells used in (B) were subjected to qRT-PCR analysis to determine the CtBP2 levels. \*\**P*\<0.001.**(D)** The CoCl~2~ treatment significantly increased Runx2 acetylation. Cells used in (B) were subjected to western blot to examine the CtBP2, p300, Runx2 and acetylated-Runx2 levels. GAPDH was used as a control. **(E)** The CoCl~2~ treatment significantly increased the expressions of Runx2 target genes. The mRNAs used in (C) were subjected to qRT-PCR analysis to determine the expressions of Runx2 target genes including *OSC*, *ALPL*, *SPP1*, *COL1A1*, *IBSP* and *MMP13*. *CUL4A* was used as a control. \*\**P*\<0.001.](ijbsv14p2023g006){#F6}

![**NDAH levels determine CtBP2 dimerization and regulate Runx2 target gene levels. (A)** The elevated NADH levels increased CtBP2 dimerization. The HOB-1 cells were transfected with a *pCDNA3-2xFlag* (control), *pCDNA3-2xFlag-CtBP2* or *pCDNA3-2xFlag-CtBP2-G189A* plasmid. After 48 hours, cells were treated with CoCl~2~ or CoCl~2~+HQNO. The treated cells were then subjected to IP analysis with anti-Flag-agarose, and the pull-down products were then subjected to western blot with anti-Flag, anti-CtBP2 and p300. GAPDH was used as an input loading control. **(B)** The elevated NADH levels increased Runx2 target gene expression. The mRNAs from cells used in (A) were subjected to qRT-PCR analysis to determine the expression of Runx2 target genes, including *OSC*, *ALPL*, *SPP1*, *COL1A1*, *IBSP* and *MMP13*. *CUL4A* was used a control. \*\**P*\<0.001.](ijbsv14p2023g007){#F7}

![**Schematic models of the CtBP2-p300-Runx2 transcriptional complex.** The working model of CtBP2-p300-Runx2 in HOB cells. In HOB cells, CtBP2 tends to form a dimer, which enhances p300 activity and increases the acetylation of Runx2, eventually initiating transcription and regulating the expression of bone development as well as the differentiation of related genes including *OSC*, *ALPL*, *SPP1*, *COL1A1*, *IBSP* and *MMP13*. **(B)** The working model of CtBP2-p300-Runx2 in AOB cells. In AOB cells, the decreased NADH level disrupts CtBP2 dimerization, which inhibits p300 activity and attenuates the acetylation of Runx2, eventually repressing the expression of Runx2 target genes.](ijbsv14p2023g008){#F8}
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